Cargando…

Management and outcome of locally advanced oral squamous cell carcinoma

Management of locally advanced OSCC is multimodal. No single therapy has been proved to be efficacious. However there is a trend towards surgical intervention in operable disease. In this review we appraise the various therapies used for the management of locally advanced OSCC. We review the literat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bera, Rathindra N., Tandon, Sapna, Singh, Akhilesh K., Boojar, Fargol M. A., Jaiswal, Gaurav, Borse, Shraddha, Pal, Uma S., Sharma, Naresh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474551/
https://www.ncbi.nlm.nih.gov/pubmed/37661995
http://dx.doi.org/10.4103/njms.njms_125_22
_version_ 1785100523305697280
author Bera, Rathindra N.
Tandon, Sapna
Singh, Akhilesh K.
Boojar, Fargol M. A.
Jaiswal, Gaurav
Borse, Shraddha
Pal, Uma S.
Sharma, Naresh K.
author_facet Bera, Rathindra N.
Tandon, Sapna
Singh, Akhilesh K.
Boojar, Fargol M. A.
Jaiswal, Gaurav
Borse, Shraddha
Pal, Uma S.
Sharma, Naresh K.
author_sort Bera, Rathindra N.
collection PubMed
description Management of locally advanced OSCC is multimodal. No single therapy has been proved to be efficacious. However there is a trend towards surgical intervention in operable disease. In this review we appraise the various therapies used for the management of locally advanced OSCC. We review the literature with regards to the various treatment options for locally advanced OSCC. We categorically divided the manuscript into resectable, unresectable and technically unresectable disease. Surgery is the ideal treatment modality for resectable disease. For unresectable disease concurrent chemoradiation appears to improve survival compared to radiotherapy alone. Induction therapy might downstage tumors in the unresectable category. Targeted and Immunotherapy is reserved for recurrent, metastatic or platinum refractory OSCC. Management of locally advanced OSCC is multimodal with surgery playing the primary role. In the event where the tumor is in operable concurrent chemoradiotherapy is regarded as the best treatment modality. Induction chemotherapy currently cannot be recommended for resectable or even unresectable oral squamous cell carcinomas. However for technically unresectable disease it might play a role in improving respectability but it depends on the response of the tumor. Targeted therapy and immunotherapy is currently used for recurrent, metastatic and/or platinum refractory Head and Neck cancers. Currently it is not recommended for initial management of locally advanced disease.
format Online
Article
Text
id pubmed-10474551
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-104745512023-09-03 Management and outcome of locally advanced oral squamous cell carcinoma Bera, Rathindra N. Tandon, Sapna Singh, Akhilesh K. Boojar, Fargol M. A. Jaiswal, Gaurav Borse, Shraddha Pal, Uma S. Sharma, Naresh K. Natl J Maxillofac Surg Review Article Management of locally advanced OSCC is multimodal. No single therapy has been proved to be efficacious. However there is a trend towards surgical intervention in operable disease. In this review we appraise the various therapies used for the management of locally advanced OSCC. We review the literature with regards to the various treatment options for locally advanced OSCC. We categorically divided the manuscript into resectable, unresectable and technically unresectable disease. Surgery is the ideal treatment modality for resectable disease. For unresectable disease concurrent chemoradiation appears to improve survival compared to radiotherapy alone. Induction therapy might downstage tumors in the unresectable category. Targeted and Immunotherapy is reserved for recurrent, metastatic or platinum refractory OSCC. Management of locally advanced OSCC is multimodal with surgery playing the primary role. In the event where the tumor is in operable concurrent chemoradiotherapy is regarded as the best treatment modality. Induction chemotherapy currently cannot be recommended for resectable or even unresectable oral squamous cell carcinomas. However for technically unresectable disease it might play a role in improving respectability but it depends on the response of the tumor. Targeted therapy and immunotherapy is currently used for recurrent, metastatic and/or platinum refractory Head and Neck cancers. Currently it is not recommended for initial management of locally advanced disease. Wolters Kluwer - Medknow 2023 2023-07-13 /pmc/articles/PMC10474551/ /pubmed/37661995 http://dx.doi.org/10.4103/njms.njms_125_22 Text en Copyright: © 2023 National Journal of Maxillofacial Surgery https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Bera, Rathindra N.
Tandon, Sapna
Singh, Akhilesh K.
Boojar, Fargol M. A.
Jaiswal, Gaurav
Borse, Shraddha
Pal, Uma S.
Sharma, Naresh K.
Management and outcome of locally advanced oral squamous cell carcinoma
title Management and outcome of locally advanced oral squamous cell carcinoma
title_full Management and outcome of locally advanced oral squamous cell carcinoma
title_fullStr Management and outcome of locally advanced oral squamous cell carcinoma
title_full_unstemmed Management and outcome of locally advanced oral squamous cell carcinoma
title_short Management and outcome of locally advanced oral squamous cell carcinoma
title_sort management and outcome of locally advanced oral squamous cell carcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474551/
https://www.ncbi.nlm.nih.gov/pubmed/37661995
http://dx.doi.org/10.4103/njms.njms_125_22
work_keys_str_mv AT berarathindran managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma
AT tandonsapna managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma
AT singhakhileshk managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma
AT boojarfargolma managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma
AT jaiswalgaurav managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma
AT borseshraddha managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma
AT palumas managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma
AT sharmanareshk managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma